MediciNova, Inc. (MNOV) investor relations documents from the company's IR site: 8 press releases. Read in-app with summaries. First-party data.
| Published | Type | Document |
|---|---|---|
| 2026-07-15 | Press release | MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (i |
| 2026-06-30 | Press release | MediciNova CEO Provides Shareholder Update |
| 2026-06-08 | Press release | MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Check |
| 2026-05-26 | Press release | MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) |
| 2026-04-27 | Press release | New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clini |
| 2026-03-16 | Press release | MediciNova to Participate at the 38th Annual ROTH Conference |
| 2026-01-29 | Press release | MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) |
| 2026-01-06 | Press release | 2026 New Year’s Greetings from the CEO |
MNOV overview · MNOV earnings · MNOV financials · MNOV KPIs · MNOV ownership · MNOV peers · MNOV filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.